Weekly High-Dose Calcitriol and Docetaxel in Metastatic Androgen-Independent Prostate Cancer

Purpose: To determine the safety and efficacy of weekly high-dose oral calcitriol (Rocaltrol, Roche Pharmaceuticals, Basel, Switzerland) and docetaxel (Taxotere, Aventis Pharmaceuticals, Bridgewater, NJ) in patients with metastatic androgen-independent prostate cancer (AIPC). Patients and Methods: Thirty-seven patients were treated with oral calcitriol (0.5 μg/kg) on day 1 followed by docetaxel (36 mg/m2) on day 2, repeated weekly for 6 weeks of an 8-week cycle. Patients maintained a reduced calcium diet and increased oral hydration. Prostate-specific antigen (PSA) response was the primary end point, which was defined as a 50% reduction in PSA level confirmed 4 weeks later. Results: Thirty of 37 patients (81%; 95% confidence interval [CI], 68% to 94%) achieved a PSA response. Twenty-two patients (59%; 95% CI, 43% to 75%) had a confirmed > 75% reduction in PSA. Eight of the 15 patients with measurable disease (53%; 95% CI, 27% to 79%) had a confirmed partial response. Median time to progression was 11.4 mo...

[1]  J. Morrow,et al.  A Phase I Study of Vitamin E, 5-Fluorouracil and Leucovorin for Advanced Malignancies , 2001, Investigational New Drugs.

[2]  D. Reardon,et al.  The vitamin D3 analog EB 1089 enhances the antiproliferative and apoptotic effects of adriamycin in MCF-7 breast tumor cells , 2000, Breast Cancer Research and Treatment.

[3]  P. Aller,et al.  Etoposide stimulates 1,25-dihydroxyvitamin D3 differentiation activity, hormone binding and hormone receptor expression in HL-60 human promyelocytic cells , 2000, Molecular and Cellular Biochemistry.

[4]  P. Hershberger,et al.  Combination of 1alpha,25-dihydroxyvitamin D(3) with dexamethasone enhances cell cycle arrest and apoptosis: role of nuclear receptor cross-talk and Erk/Akt signaling. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[5]  T. Beer,et al.  Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  T. Beer,et al.  A Phase I trial of pulse calcitriol in patients with refractory malignancies , 2001, Cancer.

[7]  P. Hershberger,et al.  Calcitriol (1,25-dihydroxycholecalciferol) enhances paclitaxel antitumor activity in vitro and in vivo and accelerates paclitaxel-induced apoptosis. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[8]  R. Dhir,et al.  Effects of vitamin D (calcitriol) on transitional cell carcinoma of the bladder in vitro and in vivo. , 2001, The Journal of urology.

[9]  S. Ackland,et al.  Simple and sensitive high-performance liquid chromatography method for the determination of docetaxel in human plasma or urine. , 2000, Journal of chromatography. B, Biomedical sciences and applications.

[10]  H. Koeffler,et al.  Induction of apoptosis by vitamin D3 analogue EB1089 in NCI‐H929 myeloma cells via activation of caspase 3 and p38 MAP kinase , 2000, British journal of haematology.

[11]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[12]  B. Freidlin,et al.  Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  B. Lembersky,et al.  A phase II trial of docetaxel (Taxotere) in hormone-refractory prostate cancer: correlation of antitumor effect to phosphorylation of Bcl-2. , 1999, Seminars in oncology.

[14]  J. Picus,et al.  Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results. , 1999, Seminars in oncology.

[15]  P. Kantoff,et al.  Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  D. Smith,et al.  A Phase I trial of calcitriol (1,25-dihydroxycholecalciferol) in patients with advanced malignancy. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[17]  G. Miller,et al.  1α,25-Dihydroxyvitamin D3 and Platinum Drugs Act Synergistically to Inhibit the Growth of Prostate Cancer Cell Lines , 1999 .

[18]  T. Stamey,et al.  Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D3 (calcitriol) , 1998, The Journal of urology.

[19]  D. Smith,et al.  Enhancement of 1,25-dihydroxyvitamin D3-mediated antitumor activity with dexamethasone. , 1998, Journal of the National Cancer Institute.

[20]  R. Day,et al.  Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system. , 1997, Urology.

[21]  Wei-dong Yu,et al.  Potentiation of cisplatin antitumor activity using a vitamin D analogue in a murine squamous cell carcinoma model system. , 1997, Cancer research.

[22]  M. Campbell,et al.  Toward therapeutic intervention of cancer by vitamin D compounds. , 1997, Journal of the National Cancer Institute.

[23]  K. Burnstein,et al.  Vitamin D receptor content and transcriptional activity do not fully predict antiproliferative effects of vitamin D in human prostate cancer cell lines , 1997, Molecular and Cellular Endocrinology.

[24]  A. Zinsmeister,et al.  1α,25-Dihydroxyvitamin D3Inhibits Normal Human Keratinocyte Growth by Increasing Transforming Growth Factor β2 Release , 1996 .

[25]  M. Hirata,et al.  Vitamin D Receptor in Endometrial Carcinoma and the Differentiation‐Inducing Effect of 1,25‐Dihydroxyvitamin D3 on Endometrial Carcinoma Cell Lines , 1996, The journal of obstetrics and gynaecology research.

[26]  N. Saijo,et al.  1 alpha, 25-dihydroxyvitamin D3 and all-trans-retinoic acid inhibit the growth of a lung cancer cell line. , 1996, Anticancer research.

[27]  A. Mackay,et al.  Effects of 1,25 dihydroxyvitamin D3 and its analogues on induction of apoptosis in breast cancer cells , 1996, The Journal of Steroid Biochemistry and Molecular Biology.

[28]  G. Miller,et al.  Vitamin D receptor expression is required for growth modulation by 1α,25-dihydroxyvitamin D3 in the human prostatic carcinoma cell line ALVA-31 , 1996, The Journal of Steroid Biochemistry and Molecular Biology.

[29]  D. Osoba,et al.  Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  M. Gottardis,et al.  Growth-inhibitory effects of vitamin D analogues and retinoids on human pancreatic cancer cells. , 1996, British Journal of Cancer.

[31]  H. Pols,et al.  Inhibition of insulin- and insulin-like growth factor-I-stimulated growth of human breast cancer cells by 1,25-dihydroxyvitamin D3 and the vitamin D3 analogue EB1089. , 1996, European journal of cancer.

[32]  B. Hollis,et al.  Quantification of circulating 1,25-dihydroxyvitamin D by radioimmunoassay with 125I-labeled tracer. , 1996, Clinical chemistry.

[33]  L. Hengst,et al.  Translational Control of p27Kip1 Accumulation During the Cell Cycle , 1996, Science.

[34]  L. Freedman,et al.  Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937. , 1996, Genes & development.

[35]  R. Day,et al.  Phase II trial of oral 1,25-dihydroxyvitamin D (calcitriol) in hormone refractory prostate cancer. , 1995, Urologic oncology.

[36]  Y. Tokuumi.  [Correlation between the concentration of 1,25 alpha dihydroxyvitamin D3 receptors and growth inhibition, and differentiation of human osteosarcoma cells induced by vitamin D3]. , 1995, Nihon Seikeigeka Gakkai zasshi.

[37]  R. Ostenson,et al.  IGF‐Binding proteins in human prostate tumor cells: Expression and regulation by 1,25‐dihydroxyvitamin D3 , 1995, The Prostate.

[38]  D. Peehl,et al.  Actions of vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3. , 1995, Endocrinology.

[39]  R. Bahnson,et al.  Human prostate cancer cells: inhibition of proliferation by vitamin D analogs. , 1994, Anticancer research.

[40]  T. Stamey,et al.  Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells. , 1994, Cancer research.

[41]  S. Jabłońska,et al.  Inhibition of tumor cell-induced angiogenesis by retinoids, 1,25-dihydroxyvitamin D3 and their combination. , 1993, Cancer letters.

[42]  K. Hashimoto,et al.  Growth inhibition of human keratinocytes by 1,25-dihydroxyvitamin D3 is linked to dephosphorylation of retinoblastoma gene product. , 1993, Biochemical and biophysical research communications.

[43]  D. Peehl,et al.  Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. , 1993, Endocrinology.

[44]  R. Coombes,et al.  Effects of synthetic vitamin D analogues on breast cancer cell proliferation in vivo and in vitro. , 1992, Biochemical pharmacology.

[45]  M. Katz,et al.  1,25‐dihydroxy‐vitamin‐D3 enhances antiproliferative effect and transcription of TGF‐β1 on human keratinocytes in culture , 1992, Journal of cellular physiology.

[46]  H. Cross,et al.  Antiproliferative effect of 1,25-dihydroxyvitamin D3 and its analogs on human colon adenocarcinoma cells (CaCo-2): influence of extracellular calcium. , 1991, Biochemical and biophysical research communications.

[47]  R. Simon,et al.  Optimal two-stage designs for phase II clinical trials. , 1989, Controlled clinical trials.

[48]  R. Isseroff,et al.  Novel regulatory actions of 1α,25‐dihydroxyvitamin D3 on the metabolism of polyphosphoinositides in murine epidermal keratinocytes , 1987 .

[49]  H. Sakagami,et al.  Differentiation of mouse myeloid leukemia cells induced by 1 alpha,25-dihydroxyvitamin D3. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[50]  D. Feldman,et al.  1,25-dihydroxyvitamin D3 and malignant melanoma: the presence of receptors and inhibition of cell growth in culture. , 1981, Endocrinology.